ClinicalTrials.Veeva

Menu
V

Valley Clinical Trials, Inc | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sugar
Retatrutide
Tirzepatide
Semaglutide
Metformin
Obicetrapib
LY3298176
Ziltivekimab
Orforglipron
LY3437943

Parent organization

This site is a part of Valley Clinical Trials, Inc

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 37 total trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling
Systemic Inflammation
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Status recently updated

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 dia...

Enrolling
Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Insuline glargine U100 (titrated)
Drug: Insuline glargine U100 (reduced)

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new invest...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Placebo

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Placebo
Drug: Semaglutide

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fract...

Enrolling
Heart Failure With Preserved Ejection Fraction
Heart Failure
Drug: Placebo
Drug: LY3540378
Locations recently updated

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: LY3556050
Drug: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo
Locations recently updated

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity
Other: Placebo
Drug: Tirzepatide

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabe...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Placebo
Drug: Tirzepatide

Trial sponsors

Lilly logo
Novo Nordisk logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
N
American Regent logo
A
Boehringer Ingelheim logo
Ionis Pharmaceuticals logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems